U.S. market Closed. Opens in 54 minutes

WVE | Wave Life Sciences Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 13.86 - 14.39
52 Week Range 3.50 - 16.74
Beta -2.16
Implied Volatility 72.70%
IV Rank 0.86%
Day's Volume 655,663
Average Volume 1,810,628
Shares Outstanding 152,520,000
Market Cap 2,174,935,200
Sector Healthcare
Industry Biotechnology
IPO Date 2015-11-11
Valuation
Profitability
Growth
Health
P/E Ratio -12.73
Forward P/E Ratio N/A
EPS -1.12
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 266
Country Singapore
Website WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
*Chart delayed
Analyzing fundamentals for WVE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see WVE Fundamentals page.

Watching at WVE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on WVE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙